196 related articles for article (PubMed ID: 11598385)
21. Design of amphotericin B oral formulation for antifungal therapy.
Liu M; Chen M; Yang Z
Drug Deliv; 2017 Nov; 24(1):1-9. PubMed ID: 28155335
[TBL] [Abstract][Full Text] [Related]
22. What is the current and future status of conventional amphotericin B?
Kleinberg M
Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():12-6. PubMed ID: 16707251
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of amphotericin B formulations: a network meta-analysis and a multicriteria decision analysis.
Tonin FS; Steimbach LM; Borba HH; Sanches AC; Wiens A; Pontarolo R; Fernandez-Llimos F
J Pharm Pharmacol; 2017 Dec; 69(12):1672-1683. PubMed ID: 28815602
[TBL] [Abstract][Full Text] [Related]
24. Liposomal formulations of amphotericin B: differences according to the scientific evidence.
Azanza JR; Sádada B; Reis J
Rev Esp Quimioter; 2015 Dec; 28(6):275-81. PubMed ID: 26621170
[TBL] [Abstract][Full Text] [Related]
25. Amphotericin B nephrotoxicity in children.
Goldman RD; Koren G
J Pediatr Hematol Oncol; 2004 Jul; 26(7):421-6. PubMed ID: 15218415
[TBL] [Abstract][Full Text] [Related]
26. Lipid amphotericin B formulations as comparators in clinical trials.
Powers JH; Albrecht R
Clin Infect Dis; 2004 Jan; 38(2):305-6; author reply 306-7. PubMed ID: 14699471
[No Abstract] [Full Text] [Related]
27. Minimizing nephrotoxicity using continuous infusion of deoxycholate amphotericin B.
Gwee A; Cranswick N; Connell TG; Curtis N
Pediatr Infect Dis J; 2014 Oct; 33(10):1098. PubMed ID: 25361191
[No Abstract] [Full Text] [Related]
28. Comparison of nephrotoxicity associated to different lipid formulations of amphotericin B: a real-life study.
Falci DR; da Rosa FB; Pasqualotto AC
Mycoses; 2015 Feb; 58(2):104-12. PubMed ID: 25590436
[TBL] [Abstract][Full Text] [Related]
29. Mechanisms and management of amphotericin B-induced nephrotoxicity.
Miano-Mason TM
Cancer Pract; 1997; 5(3):176-81. PubMed ID: 9171554
[TBL] [Abstract][Full Text] [Related]
30. Amphotericin B and its new derivatives - mode of action.
Baginski M; Czub J
Curr Drug Metab; 2009 Jun; 10(5):459-69. PubMed ID: 19689243
[TBL] [Abstract][Full Text] [Related]
31. Structural characterization of the interaction of the polyene antibiotic Amphotericin B with DODAB bicelles and vesicles.
Oliveira TR; Benatti CR; Lamy MT
Biochim Biophys Acta; 2011 Nov; 1808(11):2629-37. PubMed ID: 21839723
[TBL] [Abstract][Full Text] [Related]
32. [Liposomal amphotericin B: a unique pharmacokinetic profile. An unfinished story].
Azanza Perea JR; Barberán J
Rev Esp Quimioter; 2012 Mar; 25(1):17-24. PubMed ID: 22488537
[TBL] [Abstract][Full Text] [Related]
33. Liposomal amphotericin B for fever and neutropenia.
Patel MA; Curtis K; Maguire JH
N Engl J Med; 1999 Oct; 341(15):1153; author reply 1154-5. PubMed ID: 10515752
[No Abstract] [Full Text] [Related]
34. Drug delivery system of anti-fungal and parasitic agents.
Maesaki S
Curr Pharm Des; 2002; 8(6):433-40. PubMed ID: 12069380
[TBL] [Abstract][Full Text] [Related]
35. Liposomal drug delivery system from laboratory to clinic.
Kshirsagar NA; Pandya SK; Kirodian GB; Sanath S
J Postgrad Med; 2005; 51 Suppl 1():S5-15. PubMed ID: 16519249
[TBL] [Abstract][Full Text] [Related]
36. Redesign of antifungal polyene glycosylation: engineered biosynthesis of disaccharide-modified NPP.
Kim HJ; Kang SH; Choi SS; Kim ES
Appl Microbiol Biotechnol; 2017 Jun; 101(12):5131-5137. PubMed ID: 28488115
[TBL] [Abstract][Full Text] [Related]
37. Persistent acute tubular toxicity after switch from conventional amphotericin B to liposomal amphotericin B (Ambisome).
Gerbaud E; Tamion F; Girault C; Clabault K; Lepretre S; Leroy J; Bonmarchand G
J Antimicrob Chemother; 2003 Feb; 51(2):473-5. PubMed ID: 12562731
[No Abstract] [Full Text] [Related]
38. Are salt loading and prolonging infusion period effective in prevention of amphotericin B-induced nephrotoxicity?
Karimzadeh I; Farsaei S; Khalili H; Dashti-Khavidaki S
Expert Opin Drug Saf; 2012 Nov; 11(6):969-83. PubMed ID: 22950480
[TBL] [Abstract][Full Text] [Related]
39. Comparison between liposomal formulations of amphotericin B.
Adler-Moore JP; Gangneux JP; Pappas PG
Med Mycol; 2016 Mar; 54(3):223-31. PubMed ID: 26768369
[TBL] [Abstract][Full Text] [Related]
40. Lipid formulations of amphotericin B: clinical perspectives for the management of invasive fungal infections in children with cancer.
Groll AH; Müller FM; Piscitelli SC; Walsh TJ
Klin Padiatr; 1998; 210(4):264-73. PubMed ID: 9743964
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
